Press Releases Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Market Closed - Xetra Other stock markets 09:06:14 26/06/2024 pm IST			After market 12:19:25 am
8.5 ^EUR	-0.47%		8.49	-0.12%

05/04	Apontis Bags Distribution Deal with Novartis Unit for Two Asthma Medications	MT
28/03	Apontis Pharma AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management	04/06	EQ
DD: APONTIS PHARMA AG: Thomas Milz, buy	14/05	EQ
DD: APONTIS PHARMA AG: be executive GmbH, buy	14/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
DD: APONTIS PHARMA AG: Thomas Zimmermann, buy	13/05	EQ
Apontis Pharma : Earnings Call Q1/24 Presentation	08/05	PU
APONTIS PHARMA starts financial year 2024 with growth in revenue of Single Pill combinations and positive net result – forecast for full-year 2024 confirmed	08/05	EQ
APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast	05/04	EQ
APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications	05/04	EQ
APONTIS PHARMA expects profitable growth again in 2024	28/03	EQ
Apontis Pharma : Earnings Call 2023 Presentation	28/03	PU
APONTIS PHARMA successfully completes performance and efficiency improvement program	06/02	EQ
APONTIS PHARMA presents details of the restructuring and efficiency program – Nine-month figures for 2023 and new sales and earnings forecast for 2023 published	09/11	EQ
APONTIS PHARMA AG with new forecast 2023 and details on announced restructuring program	09/11	EQ
APONTIS PHARMA confirms preliminary figures – H1 2023 sales and earnings decline	10/23/10	EQ
APONTIS PHARMA: Co-promotion contract with AstraZeneca not to be continued in 2024	31/23/31	EQ
APONTIS PHARMA AG withdraws forecast for fiscal year 2023 and medium-term planning for 2026 – Preparation of program to increase operating performance and efficiency launched	28/23/28	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Apontis Pharma AG

Equities

APPH

DE000A3CMGM5

Press Releases

Filters